Risk factors associated with mortality in newborn infants with congenital diaphragmatic hernia

María F. Galletti, M.D., Carolina Giudice, M.D., Pablo H. Brener Dik, M.D., Silvia Fernández Jonusas, M.D., Luisa Baldini, M.D., and Gonzalo L. Mariani, M.D.

ABSTRACT
Introduction. Morbidity and mortality are high in congenital diaphragmatic hernia. Some tools help to predict survival, both prenatally (observed/expected lung-to-head ratio [OE-LHR], presence of the liver in the chest) and postnatally (Congenital Diaphragmatic Hernia Study Group [CDHSG] score). Our objective was to identify the risk factors associated with mortality and estimate the risk-adjusted mortality in the prenatal period in the subgroup of patients with isolated left-sided hernia.

Population and methods. Retrospective and analytical study of patients born at Hospital Italiano de Buenos Aires between 2011 and 2018. A multivariate analysis was done to assess mortality-associated risk factors. For risk-adjusted mortality in the prenatal period, the ratio between the observed mortality and the mean “expected” mortality based on the OE-LHR was estimated.

Results. A total of 53 patients were included. Their median gestational age was 38 weeks, and their mean birth weight was 3054 g. Isolated hernia was observed in 73 % of patients. Overall mortality was 45 %, and higher in patients with associated malformations. In the multivariate analysis, the presence of severe pulmonary hypertension estimated by postnatal echocardiogram was independently associated with mortality (adjusted odds ratio: 6.4, 95 % confidence interval: 1.02-40). The observed overall mortality in patients with isolated left-sided hernia was similar to that expected (ratio: 1.05).

Conclusion. Overall mortality was similar to that expected based on the OE-LHR. In our population, severe pulmonary hypertension after birth was a determining factor of mortality.

Key words: congenital diaphragmatic hernia, neonatal mortality, risk factors, pulmonary hypertension.

http://dx.doi.org/10.5546/aap.2020.eng.180

INTRODUCTION
Congenital diaphragmatic hernia (CDH) is an anomaly present in 1 out of every 2500-4000 newborn infants (NBIs). Overall mortality from this condition is 40-60 %; and respiratory morbidity, 15-25 %. In 85-90 % of cases, CDH is left-sided, and 30-40 % of patients have chromosome diseases or genetic disorders and associated anomalies that lead to a higher mortality.2,3

Pulmonary hypoplasia is a determining factor of morbidity and mortality. Therefore, the prediction based on prenatal risk factors has focused on ultrasound and magnetic resonance imaging of the lungs.4-7 The observed/expected lung-to-head ratio (OE-LHR) is the tool most commonly used to estimate prenatal risk. It has been validated exclusively in patients with isolated left-sided CDH and is a marker of pulmonary hypoplasia.8

The OE-LHR is combined with the presence of liver in the chest to estimate the degree of pulmonary hypoplasia and predict postnatal survival. Thus, patients with an OE-LHR < 15 % have extreme pulmonary hypoplasia with no reports of survivors; those with an OE-LHR of 15-25 % have severe pulmonary hypoplasia with a survival of 20 %; and those with an OE-LHR of 26-35 % and 36-45 % and liver in the chest have moderate pulmonary hypoplasia with a survival of 20 %. Finally, fetuses with an OE-LHR > 45 % and 36-45 % with the liver in the abdomen have mild pulmonary hypoplasia and a survival of more than 75 %.9

There is a tool available to stratify patients into categories with different risks for death in the immediate
The model includes the following outcome measures: Apgar score at 5 minutes < 7, congenital heart disease and/or chromosomal abnormalities, severe pulmonary hypertension (PHT) diagnosed by echocardiogram, and small for gestational age (SGA). This way, three groups with different probabilities of death are identified: score 0, low risk (< 10%); score 1-2, intermediate risk (25%); and score ≥ 3, high risk for mortality (50%).

PHT occurs in the postnatal period as a manifestation of pulmonary vascular alterations. However, it is difficult to predict PHT in the prenatal period with the tools currently available. A color Doppler echocardiogram is required in the postnatal period to estimate PHT. It is directly related to the degree of hypoxemia, an indicator of mortality in the short term.

In our setting, few studies on CDH have been published, so it is necessary to consult the international bibliography. It may be useful to disseminate our experience working at a facility that offers a program to care for high-risk pregnancies and a level IIIB neonatal intensive care unit, where an important number of cases may be recorded to conduct this study. Our primary objective was to identify risk factors associated with mortality in the neonatal period in a group of patients diagnosed with CDH. Our secondary objective was to estimate the risk-adjusted mortality in the prenatal period in the subgroup of patients with isolated left-sided congenital diaphragmatic hernia (LCDH).

MATERIAL AND METHODS

Design: Observational and analytical study conducted in a retrospective cohort.

Population: All NBIs with CDH who received antenatal care follow-up and were born at Hospital Italiano de Buenos Aires (HIBA) were included successively between 2011 and 2018.

Exclusion criteria: NBIs with treatment adjustment from birth were included only to estimate overall mortality. For the risk-adjusted mortality in the prenatal period, NBIs with right-sided CDH, associated major malformations and/or chromosomal abnormalities, and patients without registration of OE-LHR were excluded.

Data collection: A database was created to include the outcome measures collected from a prospective, secondary source. If any piece of data was missing, it was obtained from the electronic medical record (EMR). The following outcome measures were collected: birth weight (BW), gestational age (GA), sex, delivery mode, type of mechanical ventilation (conventional MV and/or high frequency oscillatory ventilation [HFOV]) at baseline (in the first 12 hours of life) and during hospitalization, surfactant requirement, inhaled nitric oxide (iNO), initiation of extracorporeal membrane oxygenation (ECMO), oxygenation index (OI) at baseline (first value available in the first 12 hours of life), complications during hospitalization (confirmed or clinical sepsis, pneumothorax, and chylothorax), components of prenatal (OE-LHR defined as the observed percentage of the lung volume contralateral to the lesion over that expected for each GA, presence of liver in the chest) and postnatal prediction tools. Severe PHT was defined by an echocardiogram performed in the first 24 hours of life based on foramen ovale and ductal flow.

Statistical analysis: Measures of central tendency and dispersion, based on sample distribution, were estimated for continuous outcome measures. Measures of frequency were estimated for categorical outcome measures; they were reported as percentages. A univariate analysis was performed to establish an association between studied outcome measures and mortality. The t-test or a non-parametric test were done for continuous outcome measures, based on their distribution. The χ² test or Fisher’s exact test were used for categorical outcome measures, as applicable.

A multivariate analysis was done to establish whether the components of pre- and postnatal prediction tools behaved as independent outcome measures associated with mortality. The OE-LHR and severe PHT outcome measures were included because both showed a significant association in the univariate analysis. This was only done in patients with isolated LCDH because the OE-LHR has been validated only in this population. The crude and adjusted odds ratio (OR) with the corresponding 95% confidence interval (CI) and the p-value were reported.

A receiver operating characteristic (ROC) curve was done; the area under the curve (AUC) was reported, and the Hosmer-Lemeshow test was done to assess the model’s goodness of fit. To estimate the risk-adjusted mortality in the prenatal period, the ratio between the mortality observed in our population and the mean “expected” mortality based on each patient’s OE-LHR was obtained. A value of p < 0.05 was considered significant.
Ethical considerations: The study was approved by the Ethics Committee for Research Protocols of our hospital.

RESULTS
During the study period, 16 285 NBIs were born; of them, 55 had CDH. The incidence was 3.4 ‰, which was equivalent to a mean of 7 cases per year, and overall mortality (including the 2 patients whose treatment was adjusted at birth) was 45 %. Figure 1 shows the flow chart of patients.

The baseline characteristics of included patients are described in Table 1. Among patients with isolated LCDH, survival was 59 %, whereas among those with malformations and/or genetic disorders, 36 %. Among the patients who only had congenital heart disease as an associated malformation (n = 6), 2 survived.

In relation to respiratory support, 45 patients required HFOV, 36 received iNO and 3 required ECMO. The indication for ECMO was done before surgery in 2 of these patients. The third patient required ECMO after a surgery in the setting of air leak and PHT exacerbation and survived after hospital discharge. Pulmonary surfactant was administered to 16 patients. Surgery was performed in 35 patients; 14 developed chylothorax as a postoperative complication, and 5 patients died in the postoperative period.

Table 2 shows the univariate analysis.

Compared to the group of survivors, that of dead patients had a younger GA and a lower BW, both statistically significant. The administration of iNO, surfactant, baseline OI, and HFOV requirement in the first 12 hours of life were higher among dead patients. Table 3 shows the components of pre- and postnatal prediction tools compared by mortality. In the group of dead patients, the frequency of presence of liver in the chest and severe PHT was higher. In addition, these patients tended to have a lower Apgar score at 5 minutes, together with an associated malformation and/or genetic disorder. The OE-LHR and the postnatal score were statistically significant.

**Table 1. Baseline characteristics of the population (n = 53)**

<table>
<thead>
<tr>
<th>GA in weeks; median (IQR)</th>
<th>38 (38-39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW in grams; mean (SD)</td>
<td>3054 (510)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>29 (55)</td>
</tr>
<tr>
<td>Vaginal delivery, n (%)</td>
<td>15 (28)</td>
</tr>
</tbody>
</table>

**Type of diaphragmatic hernia**
- Isolated left-sided, n (%) 39 (73)
- Associated malformations, n (%) 12 (22)

GA: gestational age; BW: birth weight; IQR: 25-75 interquartile range; SD: standard deviation.
different between them.

The multivariate analysis model included the OE-LHR and severe PHT, as pre- and postnatal predictive outcome measures. Table 4 shows the crude and adjusted OR and the area under the ROC curve. Postnatal diagnosis of severe PHT demonstrated to be an independent risk factor for mortality adjusted by the OE-LHR. The Hosmer-Lemeshow test of this model was significant ($p = 0.53$).

Lastly, the observed mortality over expected mortality based on the prenatal prediction tool (n = 36) was estimated. The expected overall mortality was 31.5%, whereas the observed overall mortality was 33.3%, with a ratio of 1.05.

**DISCUSSION**

Based on the results observed at our unit, 1 in every 300 newborn infants has CDH. This reflects a higher incidence than that reported in epidemiological studies because this is a fetal referral center. According to the bibliography, it has been demonstrated that survival is higher at facilities with a high volume of patients with CDH, which may partially explain the variation in mortality in these patients.16,17

### Table 2. Univariate analysis. Demographic and postnatal course outcome measures based on mortality

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>Survivors, n = 30</th>
<th>Non-survivors, n = 23</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GA in weeks; median (IQR)</td>
<td>39 (38-39)</td>
<td>38 (38-38)</td>
<td>0.017***</td>
</tr>
<tr>
<td>BW in grams; mean (SD)</td>
<td>3204 (±382)</td>
<td>2848 (±593)</td>
<td>0.013**</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>13 (43.3)</td>
<td>16 (69.5)</td>
<td>0.057*</td>
</tr>
<tr>
<td>Vaginal delivery, n (%)</td>
<td>10 (33.3)</td>
<td>5 (21.7)</td>
<td>0.54†</td>
</tr>
<tr>
<td>Isolated LCDH, n (%)</td>
<td>25 (83)</td>
<td>16 (60.9)</td>
<td>0.11†</td>
</tr>
<tr>
<td>Congenital heart disease, n (%)</td>
<td>2 (6.7)</td>
<td>4 (17.4)</td>
<td>0.38†</td>
</tr>
<tr>
<td>HFOV, n (%)</td>
<td>22 (73.3)</td>
<td>23 (100)</td>
<td>0.007†</td>
</tr>
<tr>
<td>Surfactant, n (%)</td>
<td>3 (10)</td>
<td>13 (56.5)</td>
<td>0.001†</td>
</tr>
<tr>
<td>iNO, n (%)</td>
<td>14 (46.6)</td>
<td>22 (95.6)</td>
<td>0.001†</td>
</tr>
<tr>
<td>Baseline AMV, n (%)</td>
<td>19 (63.3)</td>
<td>2 (8.7)</td>
<td>0.001†</td>
</tr>
<tr>
<td>Baseline HFOV, n (%)</td>
<td>11 (36.6)</td>
<td>21 (91.3)</td>
<td>0.001†</td>
</tr>
<tr>
<td>Baseline OI; median (IQR)</td>
<td>6.7 (4-10.5)</td>
<td>25.2 (15.7-31)</td>
<td>0.001***</td>
</tr>
<tr>
<td>Sepsis, n (%)</td>
<td>15 (50)</td>
<td>8 (34.8)</td>
<td>0.27</td>
</tr>
<tr>
<td>Chylothorax, n (%); n = 35</td>
<td>10 (33.3)</td>
<td>4 (80)</td>
<td>0.13†</td>
</tr>
<tr>
<td>Pneumothorax, n (%)</td>
<td>7 (23.3)</td>
<td>5 (21.7)</td>
<td>0.89†</td>
</tr>
</tbody>
</table>

GA: gestational age; BW: birth weight; LCDH: left-sided congenital diaphragmatic hernia; HFOV: high frequency oscillatory ventilation; iNO: inhaled nitric oxide; AMV: assisted mechanical ventilation; OI: oxygenation index; IQR: 25-75 interquartile range; SD: standard deviation. (*) χ². (†) Fisher. (**) T test. (***) Mann-Whitney.

### Table 3. Univariate analysis. Components of prenatal and postnatal prediction tools

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>Survivors, (n = 30)</th>
<th>Non-survivors, (n = 23)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>OE-LHR % (median and IQR); n = 36</td>
<td>48 (35-66)</td>
<td>36.5 (31-41)</td>
<td>0.04***</td>
</tr>
<tr>
<td>Liver in the chest, n (%)</td>
<td>12 (40)</td>
<td>17 (73.9)</td>
<td>0.014*</td>
</tr>
<tr>
<td>SGA, n (%)</td>
<td>2 (6.7)</td>
<td>5 (21.7)</td>
<td>0.21†</td>
</tr>
<tr>
<td>Apgar at 5 minutes &lt; 7, n (%)</td>
<td>2 (6.7)</td>
<td>7 (30.4)</td>
<td>0.06†</td>
</tr>
<tr>
<td>Severe PHT, n (%)</td>
<td>11 (36.6)</td>
<td>19 (86.3)</td>
<td>0.001†</td>
</tr>
<tr>
<td>Associated malformation, n (%)</td>
<td>5 (16.7)</td>
<td>9a= (39.1)</td>
<td>0.11†</td>
</tr>
<tr>
<td>Postnatal score, median (IQR)</td>
<td>1.5 (0-2)</td>
<td>2 (2-3)</td>
<td>0.001***</td>
</tr>
</tbody>
</table>

OE-LHR: observed/expected lung-to-head ratio; SGA: small for gestational age; PHT: pulmonary hypertension; IQR: 25-75 interquartile range. (*) χ². (†) Fisher. (**) T test. (***) Mann-Whitney.

### Table 4. Multivariate analysis assessing mortality-associated factors in patients with isolated left-sided congenital diaphragmatic hernia (n = 36)

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95 % CI)</td>
<td>p value</td>
</tr>
<tr>
<td>OE-LHR</td>
<td>0.94 (0.88-0.99)</td>
<td>0.04</td>
</tr>
<tr>
<td>Severe PHT</td>
<td>12 (2.2-7.0)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

OE-LHR: observed/expected lung-to-head ratio; PHT: pulmonary hypertension; aOR: adjusted odds ratio; CI: confidence interval. Area under the ROC curve: 0.81. Pseudo-R2 = 0.21.
In recent decades, different strategies have been implemented and demonstrated an increased survival, such as initial stabilization, delayed surgery, and HFOV, iNO, and ECMO use, among others. However, it is worth noting that survival rates may have been overestimated due to a selection bias by ignoring hidden mortality (fetal and immediate neonatal deaths before transfer). For example, Javid et al. (Canadian Neonatal Network) reported an overall survival of 82%, leaving out more severe patients who died before or during transfer and those who were directly admitted to the pediatric intensive care unit for ECMO. In our cohort, the overall survival was in the range of variability reported by epidemiological studies: Colvin et al. (Australia), 52%; Harting et al. (CDHSG), 68%. Our results correspond exclusively to patients born at our hospital, so they would account for a survival rate free of case selection.

Different mortality-associated risk factors were identified. Dead patients had a younger GA and a lower BW compared to survivors, which is similar to what has been reported by different authors. However, other studies, including a systematic review, did not find such difference. In our cohort, GA was in the range of early term. The available bibliography appears to be insufficient to establish an optimal time for birth. Stevens et al. have concluded that birth at 37-38 weeks is associated with a higher survival compared to 39-41 weeks, whereas Hutcheon et al. have demonstrated the opposite. The European consensus recommends planning a delivery after a GA of 39 weeks in a high-volume tertiary center.

Patients with CDH and associated malformations have a worse prognosis. The CDHSG reported an overall incidence of heart defects in patients with CDH of 17.8%. The most frequent heart defects included hypoplastic left heart syndrome and coarctation of the aorta, with a survival of 14% and 46%, respectively. The incidence was higher among patients with right obstructive lesions. Similarly to what has been reported, in our study, mortality in patients with associated malformations and/or disorders was almost twice as high compared to those with isolated LCDH.

In relation to health care services, in our study, dead patients more frequently received HFOV, iNO, and pulmonary surfactant. This may be due to the increased severity and the use of rescue therapies. Likewise, the group of dead patients more commonly required baseline HFOV, whereas survivors received significantly more conventional MV. A multicenter study randomized 171 patients with CDH born at 34 weeks of gestation or more to receive either conventional MV or HFOV. Although that study did not establish differences in the primary outcome measure of death/bronchopulmonary dysplasia, the group randomized to HFOV needed MV for a longer time and required more vasoactive drugs, sildenafil, iNO, and ECMO.

A study that included a multivariate analysis found an independent association between the administration of pulmonary surfactant and mortality. Beyond the observational design, that study concluded that surfactants did not provide any benefit. A meta-analysis on the use of iNO in NBIs with PHT showed that, in the subgroup of patients with CDH, iNO did not reduce the death/ECMO use outcome. However, the CDH EURO Consortium Consensus recommends considering its use if there is evidence of a right-to-left shunt through the foramen ovale and/or ductus, OI above 20 and/or a difference in pre-/post-ductal saturation above 10%, with echocardiographic evidence of an adequate left ventricular function.

Neonatal diseases with a higher ECMO requirement include meconium aspiration syndrome (MAS), CDH, PHT, sepsis, neonatal respiratory distress syndrome, among others. With the advent of therapeutic alternatives, such as surfactant, HFOV, and iNO use, the indication for ECMO has decreased drastically in this population. Among patients with CDH, ECMO indication has become a rescue strategy in the case of severe respiratory failure, with a reduction of early mortality.

A meta-analysis of retrospective studies showed a higher rate of short- and long-term survival in units where ECMO was available; according to the Extracorporeal Life Support Organization (ELSO) reports, survival was up to 74% at the time of hospital discharge. ECMO use in CDH has progressively decreased and been reserved for pre-operative stabilization of patients who meet specific criteria. At our site, where the neonatal respiratory ECMO program has been recently implemented, patients have been strictly individualized to receive this therapy.

In relation to the components of prenatal mortality prediction, the group of dead patients had a significantly higher percentage of liver herniation and a statistically lower OE-LHR score.
compared to the group of survivors, which is similar to what has been observed in the studies where they were developed. In this study, mortality was similar to that expected in patients with isolated LCDH; therefore, in this cohort of patients, the OE-LHR was, in theory, an accurate prediction tool.

The postnatal score and severe PHT, in addition to the OI, were significantly different between both groups. In the multivariate analysis, postnatal PHT diagnosis was associated with mortality, regardless of the OE-LHR, an outcome measure that lost statistical significance. It is worth noting such finding because it implies that, although this prenatal diagnostic tool is very useful, it would be wise to wait until birth to make a better prognosis. Since it is difficult to know PHT and ventricular dysfunction behavior in advance, it is necessary to perform an echocardiogram to assess ventricular discordance and structural changes in the left ventricle that may predict cardiopulmonary deterioration at birth. Prenatal methods have been proposed to estimate PHT, including lung volume and color Doppler ultrasound to observe the different pressures in the lung circuit, although they are still being studied.

This study has certain limitations. On the one side, given its design, it is not possible to establish the causality between studied risk factors and mortality. In addition, due to the number of patients, we cannot rule out the presence of a type II error. On the other side, this is the first study in our setting to assess the factors that may hinder patients’ course.

It is critical to perform both prenatal and postnatal assessments in order to identify factors and provide guidance to the families on the need to have the baby born at a tertiary care facility for a multidisciplinary approach. It may be concluded that, although there are several factors associated with mortality, in this cohort of patients, severe PHT immediately after birth was a determining factor.

REFERENCES


